Product Launch Tracker: oncologists pleased with new options for lymphomas, lung cancer and urothelial cancer

06.06.2024 | Tracker

Product Launch Tracker: oncologists pleased with new options for lymphomas, lung cancer and urothelial cancer

Throughout May 2024 CREATION.co tracked the global conversations of 1,050 HCPs who posted 1,462 tweets about the launches and approvals of new products.

In May, 382 fewer online healthcare professionals (eHCPs) discussed treatment approvals than in April, publishing 36% fewer posts during that time.

On 16 May, HCPs shared news of the FDA’s accelerated approval for Amgen’s tarlatamab for extensive stage small cell lung cancer. Oncologists Christine Lovly and Misty Dawn

Shields said the news was “practice changing” and a “HUGE victory for SCLC”.

 

Besides these clear sentiments in words, there were a pair of exclamation marks from oncologist Aman Chauhan in his post and some select emojis (namely 🚨⭐🔥) from oncologists Rami Manochakian and Vivek Subbiah to show their feelings about the FDA decision. 

On the same day a CAR-T cell therapy, Bristol Myers Squibb’s liso-cel, was approved for follicular lymphoma and later in the month for relapsed/refractory mantle cell lymphoma. For the first approval oncologist Alan Skarbnik announced the news saying he was “happy to have another CAR-T option for our patients”. 

Its approval for mantle cell lymphoma was also met warmly as it is “great to have an option with less high-grade CRS and ICANS”, said academic haematologist Ajay Major.

When the European Commission approved Bristol Myers Squibb’s nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable or metastatic urothelial carcinoma two highly followed doctors, Yüksel Ürün, a medical oncologist in Türkiye and Tom Powles, an oncologist in the UK, immediately shared the news with their online network. Their two posts received hundreds of likes, comments and shares, especially Dr Powles’ as he used the opportunity to discuss treatment guidelines.

The three most shared stories from eHCPs discussing product launches in May were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 May and 31 May 2024.  
  • The data included mentions of drug approvals by the FDA, EMA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their tweets.
  • Between 1 and 31 May 2024, 1,050 online HCPs worldwide made 1,462 references to new pharmaceutical product launches and drug approvals. 

 

Share this article

Meet the Author

Jamie Doggett

As Associate Director of Insight, Jamie leads the Analytics and Insights Team overseeing the development of insights. He works with teams to ensure the highest standards of research outputs, client delivery, and technology development.

Jamie is a country boy at heart having grown up on the sunny Isle of Wight and enjoys adventures which is reflected in a love for travel and travel literature.

Suggested next


US HCPs Raise Awareness of Pancreatic Cancer

12.12.2019 | Article

US HCPs Raise Awareness of Pancreatic Cancer

US HCPs Raise Awareness of Pancreatic Cancer

By Lara Meyer

26.10.2020 | Article

Is circulating tumour DNA testing too controversial an approach in cancer treatment? Doctors have their say online.

What are HCPs are saying about circulating tumour DNA as an approach to cancer treatment?

By Lara Meyer

View all articles >